中/EN
中文繁體
English
Investor Relations
IR Home
Corporate Overview
Financial Highlights
Financial Reports
ESG Reports
Regulatory Filings
Press Releases
Company Presentations
Stock Quotes & Charts
Analyst Coverage
FAQs
IR Contact
Corporate
Investor Relations
IR Home
Corporate Overview
Financial Highlights
Financial Reports
ESG Reports
Regulatory Filings
Press Releases
Company
Presentations
Stock Quotes &
Charts
Analyst Coverage
FAQs
IR Contact
Latest News
FEB
09
THE GROUP'S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION
FEB
05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026
FEB
03
APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA
2025
Interim Report
PDF
ESG Report 2024
Environment
Social
Governance
Presentation
Investor Information
Regulatory Filings
Corporate Governance
Stock Quotes & Charts
FAQs
IR Contact
Address
6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong
Email
tulir@tul.com.hk
